Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 25;8(6):556.
doi: 10.3390/jof8060556.

Photoinactivation of Yeast and Biofilm Communities of Candida albicans Mediated by ZnTnHex-2-PyP4+ Porphyrin

Affiliations

Photoinactivation of Yeast and Biofilm Communities of Candida albicans Mediated by ZnTnHex-2-PyP4+ Porphyrin

Sueden O Souza et al. J Fungi (Basel). .

Abstract

Candida albicans is the main cause of superficial candidiasis. While the antifungals available are defied by biofilm formation and resistance emergence, antimicrobial photodynamic inactivation (aPDI) arises as an alternative antifungal therapy. The tetracationic metalloporphyrin Zn(II) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin (ZnTnHex-2-PyP4+) has high photoefficiency and improved cellular interactions. We investigated the ZnTnHex-2-PyP4+ as a photosensitizer (PS) to photoinactivate yeasts and biofilms of C. albicans strains (ATCC 10231 and ATCC 90028) using a blue light-emitting diode. The photoinactivation of yeasts was evaluated by quantifying the colony forming units. The aPDI of ATCC 90028 biofilms was assessed by the MTT assay, propidium iodide (PI) labeling, and scanning electron microscopy. Mammalian cytotoxicity was investigated in Vero cells using MTT assay. The aPDI (4.3 J/cm2) promoted eradication of yeasts at 0.8 and 1.5 µM of PS for ATCC 10231 and ATCC 90028, respectively. At 0.8 µM and same light dose, aPDI-treated biofilms showed intense PI labeling, about 89% decrease in the cell viability, and structural alterations with reduced hyphae. No considerable toxicity was observed in mammalian cells. Our results introduce the ZnTnHex-2-PyP4+ as a promising PS to photoinactivate both yeasts and biofilms of C. albicans, stimulating studies with other Candida species and resistant isolates.

Keywords: Zn(II) porphyrin; antimicrobial photodynamic inactivation; blue light; fungi; photodynamic therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Box plots of photoinactivation of C. albicans yeasts. Two different strains were assessed, ATCC 10231 and ATCC 90028. Control: untreated group; dark: yeasts incubated with 1.5 µM of ZnP hexyl without irradiation; light: yeasts irradiated only (4.3 J/cm2). The values on the ‘x’ axis indicate the concentrations of ZnP hexyl for different aPDI groups. Differences between groups were analyzed by the Mann–Whitney test and considered significant at p < 0.05. The results are expressed as log10 of the CFU/mL. At least three independent experiments were performed. *: p < 0.05 compared to control.
Figure 2
Figure 2
Box plot of cell viability of C. albicans ATCC 90028 biofilms assessed through MTT assay following treatment. Control: untreated biofilms; dark: biofilms incubated with 1.5 µM of ZnP hexyl without irradiation; light: biofilms irradiated only (4.3 J/cm2). aPDI was performed for biofilms incubated with 0.8 µM of ZnP hexyl for 10 min followed by irradiation (4.3 J/cm2). The results were expressed in relation to untreated biofilms. Differences between groups were analyzed by the Man–Whitney test and considered significant at p < 0.05. At least three independent experiments were performed. *: p < 0.05 compared to control.
Figure 3
Figure 3
Representative confocal microscopy images of C. albicans ATCC 90028 biofilms grown for 48 h and stained with PI after treatments. Control (A): biofilm without irradiation; dark (B): biofilm incubated with 1.5 µM of ZnP hexyl without irradiation; light (C): biofilm irradiated only (4.3 J/cm2); aPDI (D): biofilm incubated with 0.8 µM of ZnP hexyl for 10 min followed by irradiation (4.3 J/cm2).
Figure 4
Figure 4
Representative SEM images of C. albicans ATCC 90028 biofilms grown for 48 h and submitted to different treatments. Control (A): biofilm without irradiation; dark (B): biofilm incubated with 1.5 µM of ZnP hexyl without irradiation; light (C): biofilm irradiated only (4.3 J/cm2); aPDI (D): biofilm incubated with 0.8 µM of ZnP hexyl for 10 min prior to irradiation (4.3 J/cm2). Yellow arrows indicate hyphae entanglements. Yellow stars indicate the exposed substrate.
Figure 5
Figure 5
Box plot of cell viability of Vero cells assessed through MTT assay following treatment. Control: untreated cells; dark: cells incubated with 1.5 µM of ZnP without irradiation; light: cells irradiated in PBS only (4.3 J/cm2). Photodynamic treatment was performed for cells incubated with 0.8 or 1.5 µM of ZnP for 10 min followed by irradiation (4.3 J/cm2). The results were expressed in relation to untreated samples. Differences between groups were analyzed by Mann–Whitney test and considered significant at p < 0.05). At least three independent experiments were performed. *: p < 0.05 compared to control. ns: not significantly different, p > 0.05.

Similar articles

Cited by

References

    1. Havlickova B., Czaika V.A., Friedrich M. Epidemiological Trends in Skin Mycoses Worldwide. Mycoses. 2008;51((Suppl. 4)):2–15. doi: 10.1111/j.1439-0507.2008.01606.x. - DOI - PubMed
    1. Bongomin F., Gago S., Oladele R.O., Denning D.W. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. J. Fungi. 2017;3:57. doi: 10.3390/jof3040057. - DOI - PMC - PubMed
    1. Nobile C.J., Johnson A.D. Candida albicans Biofilms and Human Disease. Annu. Rev. Microbiol. 2015;69:71–92. doi: 10.1146/annurev-micro-091014-104330. - DOI - PMC - PubMed
    1. Patil S., Rao R.S., Majumdar B., Anil S. Clinical Appearance of Oral Candida Infection and Therapeutic Strategies. Front. Microbiol. 2015;6:1391. doi: 10.3389/fmicb.2015.01391. - DOI - PMC - PubMed
    1. Hurley R., De Louvois J. Candida Vaginitis. Postgrad. Med. J. 1979;55:645–647. doi: 10.1136/pgmj.55.647.645. - DOI - PMC - PubMed